- Home
- SLDB vs CERS Comparison
SLDB vs CERS Comparison
Compare SLDB & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLDB
- CERS
- Stock Information
- Founded
- SLDB 2013
- CERS 1991
- Country
- SLDB United States
- CERS United States
- Employees
- SLDB N/A
- CERS N/A
- Industry
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- CERS EDP Services
- Sector
- SLDB Health Care
- CERS Technology
- Exchange
- SLDB Nasdaq
- CERS Nasdaq
- Market Cap
- SLDB 234.8M
- CERS 277.2M
- IPO Year
- SLDB 2018
- CERS 1997
- Fundamental
- Price
- SLDB $7.00
- CERS $1.39
- Analyst Decision
- SLDB Strong Buy
- CERS Strong Buy
- Analyst Count
- SLDB 10
- CERS 2
- Target Price
- SLDB $15.10
- CERS $3.50
- AVG Volume (30 Days)
- SLDB 1.7M
- CERS 1.1M
- Earning Date
- SLDB 08-12-2025
- CERS 08-05-2025
- Dividend Yield
- SLDB N/A
- CERS N/A
- EPS Growth
- SLDB N/A
- CERS N/A
- EPS
- SLDB N/A
- CERS N/A
- Revenue
- SLDB N/A
- CERS $185,144,000.00
- Revenue This Year
- SLDB N/A
- CERS $20.97
- Revenue Next Year
- SLDB N/A
- CERS $15.55
- P/E Ratio
- SLDB N/A
- CERS N/A
- Revenue Growth
- SLDB N/A
- CERS 13.06
- 52 Week Low
- SLDB $2.41
- CERS $1.12
- 52 Week High
- SLDB $10.37
- CERS $2.54
- Technical
- Relative Strength Index (RSI)
- SLDB 75.71
- CERS 48.50
- Support Level
- SLDB $5.74
- CERS $1.35
- Resistance Level
- SLDB $7.12
- CERS $1.47
- Average True Range (ATR)
- SLDB 0.48
- CERS 0.07
- MACD
- SLDB 0.11
- CERS -0.01
- Stochastic Oscillator
- SLDB 94.50
- CERS 22.73
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.